*4.16. RNA Interference*

Small interfering RNA (siRNA) duplexes were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA; siRNA targeting BCL10, sc-29793; and control siRNA, sc-37007). The CL-48 cells were transfected with siRNA at a concentration of 25 nM in serum-free Opti-MEM using Oligofectamine (Invitrogen, Carlsbad, CA, USA).

#### *4.17. Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)*

We quantified mRNA expression under various conditions while using a fluorescence quantitative real-time PCR detection system (Light Cycler DNA master SYBR Green I; Roche Molecular Biochemicals, Indianapolis, IN, USA). The primer pairs were as follows: human BAFF-R: 5-AGACAAGGACGCCCCAGAGCCC-3 and 5-GTGGGGTGGTTCCTGGGTCTTC-3; hMMP-9: 5-CACTGTCCACCCCTCAGAGC-3 and 5-GCCACTTGTCGGCGATAAGG-3; *IL-8*: 5-TTTCTGCA GCTCTCTGTGAGG-3 and 5-CTGCTGTTGTTGTTGCTTCTC-3; FGF4: 5-GACTACCTGCTGGGCA TCAA-3 and 5-TGCACTCATCGGTGAAGAAG-3; glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), 5-GGGAAGGTGAAGGTCGG-3 and 5-TGGACTCCACGACGTACTCAG-3. Amplification was followed by melting curve analysis to verify the authenticity of the amplicon. The amounts of BAFFR, MMP-9, FGF4, and IL-8 mRNAs were normalized to that of GAPDH mRNA and they are presented in arbitrary units, with 1 U corresponding to the value in cells that were treated with the vehicle control.

#### *4.18. NF-*κ*B Promoter Reporter Assays*

Transfection with NF-κB binding site-driven luciferase plasmid (BD Bioscience) into CL-48 cells was performed while using Transfast transfection reagen<sup>t</sup> (Promega, Madison, WI, USA). At 24 h after transfection, the cells were serum starved for 24 h and then treated as indicated.
